Dr. Diane Tseng, MD, PhD

Dr. Tseng practices at Fred Hutchinson Cancer Center in Seattle, Washington, part of Fred Hutchinson Cancer Center.

Dr. Tseng's NPI, 1164862785, was assigned on June 27, 2013. Dr. Tseng holds Washington license MD61038846.

Dr. Tseng's primary practice is Fred Hutchinson Cancer Center, at 825 Eastlake Avenue East, Seattle, WA 98109.

Dr. Tseng's primary practice is Fred Hutchinson Cancer Center in Seattle, Washington, part of Fred Hutchinson Cancer Center. Dr. Tseng is also affiliated with UW Medical Center - Montlake. The medical group on file is UW Physicians.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tseng practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Tseng's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Tseng is licensed in Washington.

CMS data shows 298 Medicare services from Dr. Tseng across 5 procedure codes in 2024, for 76 Medicare patients. Medicare paid $22,708 for them. Every service was in an office.

CMS counts 76 Medicare patients who saw Dr. Tseng in 2024. The largest group is 65 to 74, with 36 patients. 75% of them have cancer, and 66% have high blood pressure. 16% are also on Medicaid. Their average risk score is 2.76, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Tseng's median patient age at 70, with 59% women.

In 2024, Dr. Tseng wrote 130 Medicare Part D claims for 33 patients. 68% of them were for generic drugs. CMS names the drug for 47 of them, across 3 drugs with 11 or more claims each, at $748 in total drug cost. In 2023, CMS named 34 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Tseng for performance year 2024, reported through an alternative payment model (APM). Dr. Tseng accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Tseng as offering telehealth.

Dmand AI links 16 papers to Dr. Tseng, published from 2010 to 2025. 2011 was the busiest year, with 2. The most frequent topics are Immune Checkpoint Inhibitors, Carcinoma, Non-Small-Cell Lung and Lung Neoplasms. Dr. Tseng's most frequent co-authors are Heather Ann Wakelee, MD, Christina Seung Baik, MD and Sylvia Mina Lee, MD.

CMS Open Payments shows 3 general payments to Dr. Tseng from 2 drug and device companies in 2025. Grants make up the largest share, 98% of the total. Genentech, Inc. paid the most, $99,996.